FY24 facilities to j atrf BDP facility improvements
Active Awarded Last action
- Contract number
- 75N91024F00031
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $413,982
Award facts
- Contract value 100% obligated
- $413,982.00 Current and potential, with all options
- Completion date 89% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $23,458 | |
| Original award | $390,524 |
About this award
The National Cancer Institute awarded a $413,982 cost-plus-fixed-fee delivery order to Leidos Biomedical Research Inc. for Fiscal Year 2024 facility improvements at the J ATRF facility in Frederick, Maryland. The contract, awarded on September 26, 2024, with an ultimate completion date of January 27, 2027, carries no set-aside designation. Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., operates as a Federally Funded Research and Development Center contractor specializing in biomedical research and facilities support services for the National Institutes of Health and National Cancer Institute. The company's expertise encompasses scientific research infrastructure, facility management, and advanced technical solutions supporting the federal government's cancer research mission.
This delivery order represents ongoing facility infrastructure investment consistent with NCI's commitment to maintaining and enhancing its research capabilities at the Frederick National Laboratory for Cancer Research campus. Leidos Biomedical Research Inc. brings extensive experience managing complex, multi-year facility improvement projects and providing comprehensive laboratory and research support services across the federal biomedical research enterprise. The cost-plus-fixed-fee pricing structure is standard for this contractor's work with NCI and allows for flexibility in managing facility improvement projects while maintaining cost control through the fixed-fee component.
Quick answers
Who was awarded contract 75N91024F00031?
75N91024F00031 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 26, 2024.
How much is contract 75N91024F00031 worth?
The government has obligated $413,982 on 75N91024F00031.
Is contract 75N91024F00031 an order under another contract?
Yes. 75N91024F00031 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91024F00031 competed?
The extent of competition for 75N91024F00031 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award